Ontology highlight
ABSTRACT: Background
Anti-VEGF therapy reduces tumor blood vessels, however, some vessels always remain. These VEGF insensitive vessels may help support continued tumor growth and metastases. Many in vitro assays examining multiple steps of the angiogenic process have been described, but the majority of these assays are sensitive to VEGF inhibition. There has been little focus on the development of high-throughput, in vitro assays to model the vessels that are insensitive to VEGF inhibition.Methods
Here, we describe a fixed end-point and kinetic, high-throughput stem cell co-culture model of cord formation.Results
In this system, cords develop within 24 hours, at which point they begin to lose sensitivity to VEGF inhibitors, bevacizumab, and ramucirumab. Consistent with the h
SUBMITTER: Falcon BL
PROVIDER: S-EPMC3648446 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature